US · Healthcare · Biotechnology
EPS came in at -0.54 against a street estimate of -0.01 — a miss of 5300.0%.
with an average price target of $27.54.
CONFIDENT Caris delivered record Q2 volume (+18% YoY, 59,200 cases) driven by commercial reorganization gains. Raised FY26 revenue guidance to $1.03–1.04B (+27–28% growth). Launching Detect early-detection test, MRD assay, and MI Clarity V2 to expand market reach. Q2 2026 No geographic breakdown provided. Analysts probed volume acceleration drivers (sales maturation), new product timing (Detect excluded from guidance pending 1–2 quarters history), and competitive positioning (Brian emphasized secular adoption of comprehensive vs. narrow panels). Management confident in back-half momentum but cautious on quantifying new launches until proven. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 10.89% |
| Sixth Street Partners Management Company, L.P. | 5.09% |
| J. H. Whitney Equity Partners VI, LLC | 3.98% |
| Coatue Management LLC | 3.47% |
| BRAIDWELL LP | 2.83% |
| PointState Capital LP | 2.60% |
| T. Rowe Price Investment Management,Inc. | 1.98% |
| BlackRock Inc | 1.72% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 CARIS LIFE SCIENCES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial data disclosed – This Form 8-K contains no quantitative results, earnin | 2026-09-14 |
| Quarterly report · Q2 2026 CARIS LIFE SCIENCES, INC. – FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Total Revenue (6 months 2026): $479,886 thousa | 2026-08-05 |
| Results announced · Q3 2026 CARIS LIFE SCIENCES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $263.7 million, up 45% year-over-year (vs. $181.4 mi | 2026-08-05 |
| Shareholder vote results · Q2 2026 CARIS LIFE SCIENCES, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 4, 2026 • 282,662,545 total shares outstanding | 2026-06-05 |
| Quarterly report · Q1 2026 CARIS LIFE SCIENCES, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Total Revenue: $216.2 million (up 79% from $120.9 million in Q1 2025) | 2026-05-08 |
| Results announced · Q2 2026 CARIS LIFE SCIENCES Q1 2026 FINANCIAL RESULTS HEADLINE NUMBERS • Total revenue: $216.2 million, up 79% year-over-year (prior year: $120.9 million) • | 2026-05-07 |
| Proxy statement · Q2 2026 CARIS LIFE SCIENCES, INC. – PROXY STATEMENT SUMMARY --- CEO COMPENSATION • David Dean Halbert (Founder, Chairman, CEO) – Total compensation figures | 2026-04-23 |
| Material agreement · Q2 2026 CARIS LIFE SCIENCES, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company entered into new senior secured credit facility on April 1, 2026 • Initial T | 2026-04-02 |
Readable in the app.
| Announcement | Date |
|---|---|
| Raises 2026 revenue guidance to $1.03-$1.04 billion, representing 27-28% growth Caris Life Sciences reported strong Q2 2026 results with 45% revenue growth to $263.7 million, driven by increased molecular profiling services. The company processed approximately 59,200 cl | 2026-08-05 |
| Full year 2026 revenue guidance provided: $1.0-1.02 billion range Caris Life Sciences, a precision medicine company, reported exceptional financial results for 2025. The company achieved 97% full-year revenue growth to $812 million, driven by strong demand | 2026-02-26 |
| Raises 2025 revenue guidance to $720-730 million, 75-77% YoY growth Caris Life Sciences reported exceptional Q3 2025 results with revenue of $216.8 million, up 113% year-over-year, driven by strong molecular profiling services growth of 121%. The company com | 2025-11-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Caris Life Sciences, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.